{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:33:30Z","timestamp":1790836410913,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ferring SAS France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40258-017-0361-7","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T05:49:28Z","timestamp":1510206568000},"page":"65-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Paul","family":"Barriere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Porcu-Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Hamamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"361_CR1","unstructured":"ESHRE ART fact sheet (October 2016). Available from: \n                        https:\/\/www.eshre.eu\/Press-Room\/Resources.aspx\n                        \n                    . Accessed 23 February 2017."},{"key":"361_CR2","unstructured":"Biomedicine Agency (2015). Available from: \n                        https:\/\/www.agence-biomedecine.fr\/annexes\/bilan2015\/donnees\/procreation\/01-amp\/synthese.htm\n                        \n                    . Accessed 25 February 2017."},{"key":"361_CR3","unstructured":"Biomedicine Agency (2017). Available from: \n                        https:\/\/www.procreation-medicale.fr\n                        \n                    . Accessed 23 February 2017."},{"key":"361_CR4","unstructured":"Advanced Fertility Center of Chicago (AFCC). Ovarian Stimulation IVF Protocols Medications and Drugs for In Vitro Fertilization. Available at: \n                        http:\/\/www.advancedfertility.com\/ivfstim.htm\n                        \n                    . Accessed 23 February 2017."},{"key":"361_CR5","unstructured":"Service Public France. Assistance m\u00e9dicale \u00e0 la procr\u00e9ation (AMP). Available at: \n                        https:\/\/www.service-public.fr\/particuliers\/vosdroits\/F31462\n                        \n                    . Accessed 23 February 2017."},{"key":"361_CR6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/humupd\/dmq013","volume":"16","author":"MP Connolly","year":"2010","unstructured":"Connolly MP, Hoorens S, Chambers GM. The costs and consequences of assisted reproductive technology: an economic perspective. Hum Reprod Update. 2010;16:603\u201313.","journal-title":"Hum Reprod Update."},{"key":"361_CR7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.rbmo.2010.05.005","volume":"21","author":"J Wex-Wechowski","year":"2010","unstructured":"Wex-Wechowski J, Abou-Setta AM, Kildegaard Nielsen S, Kennedy R. HP-HMG versus rFSH in treatments combining fresh and frozen IVF cycles: success rates and economic evaluation. Reprod Biomed Online. 2010;21:166\u201378.","journal-title":"Reprod Biomed Online."},{"key":"361_CR8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3109\/09513590.2013.788641","volume":"29","author":"C Alviggi","year":"2013","unstructured":"Alviggi C, Cogningni GE, Morgante G, Cometti B, Ranieri A, Strina I, Fillicori M, De Leo V, De Placido GA. prospective randomized investigator-blind controlled, clinical study on the clinical efficacy and tolerability on two high purified hMG preparations administrated subcutaneously in women undergoing IVF. Gynecol Endocrinol. 2013;29:695\u20139.","journal-title":"Gynecol Endocrinol"},{"key":"361_CR9","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","volume":"21","author":"AN Anderssen","year":"2006","unstructured":"Anderssen AN, Devroey P. Arce JC for the MERIT Group. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21:3217\u201327.","journal-title":"Hum Reprod"},{"issue":"9","key":"361_CR10","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1093\/humrep\/dem221","volume":"22","author":"S Ziebe","year":"2007","unstructured":"Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce JC, MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod. 2007;22(9):2404\u201313.","journal-title":"Hum Reprod"},{"key":"361_CR11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","volume":"3","author":"P Devroey","year":"2012","unstructured":"Devroey P, Pellicer A, Andersen AN, Arce JC, Menopur in GnRH Antagonist Cycles with Single Embryo Transfer (MEGASET) Trial Group. A randomized assessor\u2014blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;3:561\u201371.","journal-title":"Fertil Steril."},{"key":"361_CR12","first-page":"12","volume":"23","author":"P Troude","year":"2012","unstructured":"Troude P, Bailly E, Guibert J, Bouyer J, de La Rochebrochard E, DAIFI Group. Who does not participate in a follow-up postal study? A survey of infertile couples treated by in vitro fertilization. BMC Med Res Methodol. 2012;23:12\u2013104.","journal-title":"BMC Med Res Methodol."},{"key":"361_CR13","unstructured":"Agence de la Biom\u00e9decine. Activit\u00e9 d\u2019Assistance M\u00e9dicale \u00e0 la Procr\u00e9ation 2011. Available at: \n                        http:\/\/www.agence-biomedecine.fr\/annexes\/bilan2012\/donnees\/procreation\/01-amp\/pdf\/amp.pdf\n                        \n                    . Accessed 10 September 2013."},{"key":"361_CR14","first-page":"CD005354","volume":"2","author":"M Wely Van","year":"2011","unstructured":"Van Wely M, Kwan I, Burt AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;2:CD005354.","journal-title":"Cochrane Database Syst Rev"},{"key":"361_CR15","first-page":"010290","volume":"9","author":"NS Weiss","year":"2015","unstructured":"Weiss NS, Nahuis M, Bayram N, Mol BW, Van der Veen F, van Wely M. Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst Rev. 2015;9:010290.","journal-title":"Cochrane Database Syst Rev"},{"key":"361_CR16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.fertnstert.2008.01.034","volume":"91","author":"J Wechowski","year":"2009","unstructured":"Wechowski J, Connolly M, Schneider D, et al. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha. Fertil Steril. 2009;91:1067\u201376.","journal-title":"Fertil Steril."},{"key":"361_CR17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1472-6483(10)60402-6","volume":"17","author":"M Connolly","year":"2008","unstructured":"Connolly M, De Vrieze K, Ombelet W, et al. A cost per live birth comparison of HMG and rFSH randomized trials. Reprod Biomed Online. 2008;17:756\u201363.","journal-title":"Reprod Biomed Online."},{"key":"361_CR18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0015-0282(03)02185-X","volume":"80","author":"A Lloyd","year":"2003","unstructured":"Lloyd A, Kennedy R, Hutchinson J, Sawyer W. Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction. Fertil Steril. 2003;80:1108\u201313.","journal-title":"Fertil Steril."},{"issue":"6","key":"361_CR19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40258-016-0259-9","volume":"14","author":"V Fragoulakis","year":"2016","unstructured":"Fragoulakis V, Pescott CP, Smeenk JM, van Santbrink EJ, Oosterhuis GJ, Broekmans FJ, Maniadakis N. economic evaluation of three frequently used gonadotrophins in assisted reproduction techniques in the management of infertility in the Netherlands. Appl Health Econ Health Policy. 2016;14(6):719\u201327.","journal-title":"Appl Health Econ Health Policy."},{"key":"361_CR20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.gyobfe.2004.05.002","volume":"32","author":"J Mouzon De","year":"2004","unstructured":"De Mouzon J, Allavena E, Schmitt C, Frappe M. In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost. Gynecol Obstet Fertil. 2004;32:508\u201318.","journal-title":"Gynecol Obstet Fertil"},{"key":"361_CR21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/CEOR.S48994","volume":"5","author":"J Wex","year":"2013","unstructured":"Wex J, Abou-Setta AM. Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization\/intracytoplasmic sperm-injection cycles in Sweden. Clinico Econ Outcomes Res. 2013;5:381\u201397.","journal-title":"Clinico Econ Outcomes Res"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-017-0361-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-017-0361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-017-0361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T03:37:01Z","timestamp":1517542621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-017-0361-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s40258-017-0361-7","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}